Alexandria Real Estate Equities, Inc. (ARE) stock analysis
Real Estate · REIT - Office
From the 10-K filed 2026-01-26
How it makes money
Life science companies pay rental revenue for specialized lab space, with 53% coming from investment-grade or large-cap tenants.
The company earns revenue by leasing specialized real estate to life science organizations, including pharmaceutical corporations, biotechnology firms, government research agencies, and academic institutions. Tenants pay rent for properties located within concentrated innovation clusters designed specifically for research and development.
Profitability depends on maintaining high occupancy levels, stable rental collections, contractual rent escalations, and long lease terms with high-credit tenants. Additionally, the company operates a venture capital platform that provides strategic capital directly to life science companies.
What protects it: the moat
Management claims long-standing industry relationships and curated innovation clusters help retain tenants and protect property asset values.
The company relies on its specialized Megacampus strategy to protect its rental income. By clustering properties near top academic and medical research institutions, management aims to create collaborative environments that help tenants recruit and retain scientific talent.
Management claims its deep industry relationships, rigorous tenant underwriting, and location strategy allow it to sustain high occupancy and long lease commitments. However, these competitive advantages are primarily assertions by management rather than independently verifiable moats.
What growth costs
Growing and maintaining rental earnings requires continuous capital investment in property acquisitions, construction projects, and building quality improvements.
To expand its business, the company must commit substantial capital to acquiring land and existing buildings in target innovation clusters. Growth also demands funding ground-up construction and complex redevelopment projects to transform standard real estate into specialized laboratory environments.
Maintaining existing earnings requires ongoing property expenditures to upgrade building infrastructure, improve common areas, and maintain curated amenities. If building maintenance and operational costs rise faster than expected, the company may be unable to pass those expenses to tenants.
What could damage it
A funding drought in the life science sector could prevent biotech tenants from paying rent, collapsing property cash flows and occupancy.
Because the company relies exclusively on life science tenants, its business is highly vulnerable to funding availability across biotechnology and healthcare sectors. Early and mid-stage biotech companies depend on venture capital funding, public equity markets, and research grants to fund operational burn rates.
If market disruptions or reduced research funding prevent these tenants from securing capital, tenant insolvencies would rise. Vacancies in highly customized lab space cannot easily be filled by traditional commercial tenants, leading to severe rental income decline and asset impairment.
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc., is a mission-driven life science REIT. The firm is pioneered the life science real estate niche. The firm is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus ecosystems in AAA life science and advanced technology innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. Alexandria Real Estate Equities, Inc. was established on 5th January 1994 and was incorporated in Maryland.